20 19 12 10 The National Medical Insurance Bureau issued the Opinions on Doing a Good Job in the Current Drug Price Management, clearly deepening the reform of the centralized drug procurement system, adhering to the direction of "purchasing with quantity, linking quantity and price, and integrating recruitment and procurement" to promote the return of drug prices to a reasonable level.
The drugs involved in the document are determined by the joint procurement meeting and consulting experts. Chinese herbal medicines, Chinese patent medicines and biological agents are not included. In 2022, the national centralized drug procurement has been carried out in six batches, and 234 kinds of drugs have been purchased, with an average price reduction of 53%, accounting for 30% of the total annual drug procurement of public medical institutions.
Development reasons
1, decoupling of quantity and price.
In the current bidding procurement, generally only the price is used instead of the quantity, so it is difficult for enterprises to achieve a sharp drop in drug prices because there is no sales expectation.
2. Insufficient competition.
The quality level of generic drugs is generally low, so it is difficult to compete fairly with the original drugs. The price of some original drugs has been significantly higher than that of neighboring countries and regions for a long time, and the "patent cliff" has not happened in China.
3. Decentralized procurement.
Low purchasing level and scattered power lead to insufficient bargaining power, and regional policy differences affect the formation of a unified market and weaken the market competition mechanism.
4. Lack of policy coordination.
Measures such as drug procurement, use, medical insurance payment, payment and settlement are not coordinated enough to play a synergistic role.